DFF supports patient-centered education at Brigham and Women’s Hospital to close critical gaps in awareness around rare but dangerous uterine tumors.
By expanding access to clear, evidence-based resources, DFF helps women make informed decisions—earlier, and with confidence.
Lead Investigator: Mobolaji Ajao, MD, MPH
Institution: Brigham and Women’s Hospital, Department of Obstetrics and Gynecology
Clinical Challenge
- Benign uterine fibroids (leiomyomas) are extremely common, affecting up to 80% of women. In rare cases, however, malignant tumors may arise within or be masked by benign fibroids, posing a serious and often life-threatening risk.
- Currently, no effective screening tools exist to distinguish malignant tumors from benign fibroids before symptoms become advanced, underscoring the need for early detection and accessible patient education.
Innovation
- Brigham and Women’s Hospital establishing a Center of Excellence for Fibroids and Complex Uterine Anomalies to lead a multidisciplinary effort integrating high-resolution imaging, genomics, pathology, and surgical innovation.
- The Center is committed to advancing understanding of malignant transformation, identifying women at highest risk, and developing early-detection strategies and personalized treatment pathways.
DFF-Funded Approach
- Provide critical resources to develop new educational tools for patients.
- Support creation of the MGB Fibroid Website, a patient-focused resource that combines the expertise of Brigham and Women’s Hospital and Mass General Hospital to provide accurate, up-to-date information for a broader patient community.
Impact
- Expand patient education and engagement, ensuring women have the information and resources needed for timely care.
- Leverage digital platforms and outreach to deliver clear, accessible, and evidence-based information to women worldwide.
“Thanks to your support, we are developing new patient education resources like the Mass General Brigham Fibroid Website. Your support helps ensure patients will have access to accurate, evidence-based information to make informed decisions about their care. Your generosity is helping us advance important fibroid resources and patient empowerment in meaningful ways.” Mobolaji O. Ajao, MD, MPH
